<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Sarepta Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc</link>
<description>Latest news and press releases for Sarepta Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 22 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/sarepta-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835c38b78dffbe2df119cbb.webp</url>
<title>Sarepta Therapeutics Inc</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc</link>
</image>
<item>
<title>Sarepta Therapeutics to Announce First Quarter 2026 Financial Results</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-announce-first-quarter-2026-financial-results</guid>
<pubDate>Wed, 22 Apr 2026 12:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 22, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report first quarter 2026 financial results after the Nasdaq Global Market closes on Wednesday, May 6, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss these results.</description>
</item>
<item>
<title>Sarepta Announces First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1</guid>
<pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
<description>In early clinical results, Sarepta’s αvβ6 integrin-targeted siRNA approach achieves high muscle concentrations without dose limiting toxicity for FSHD1 and</description>
</item>
<item>
<title>Sarepta to Share First Clinical Data from siRNA Pipeline Targeting FSHD1 and DM1</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-to-share-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-to-share-first-clinical-data-from-sirna-pipeline-targeting-fshd1-and-dm1</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced</description>
</item>
<item>
<title>Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-provides-regulatory-update-on-amondys-45r-and-vyondys-53r</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-provides-regulatory-update-on-amondys-45r-and-vyondys-53r</guid>
<pubDate>Thu, 19 Mar 2026 04:00:00 GMT</pubDate>
<description>– Following feedback from FDA, Company intends to submit supplemental new drug applications to FDA by the end of April 2026 requesting conversion to</description>
</item>
<item>
<title>Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-that-screening-and-enrollment-are-underway-in-endeavor-cohort-8-to-evaluate-enhanced-immunosuppression-regimen-as-part-of-elevidys-gene-therapy-for-non-ambulant-individuals-with-duchenne</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-that-screening-and-enrollment-are-underway-in-endeavor-cohort-8-to-evaluate-enhanced-immunosuppression-regimen-as-part-of-elevidys-gene-therapy-for-non-ambulant-individuals-with-duchenne</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>- Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study - The enhanced</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-call-for-applications-for-the-9th-annual-route-79-the-duchenne-scholarship-program</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-call-for-applications-for-the-9th-annual-route-79-the-duchenne-scholarship-program</guid>
<pubDate>Fri, 27 Feb 2026 05:00:00 GMT</pubDate>
<description>– Applications for the 2026-2027 academic year will be accepted until May 15, 2026 – Scholarships will be awarded to up to 20 individuals living with</description>
</item>
<item>
<title>Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-present-new-long-term-and-safety-data-across-gene-therapy-and-exon-skipping-programs-at-2026-muscular-dystrophy-association-clinical-and-scientific-congress</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-present-new-long-term-and-safety-data-across-gene-therapy-and-exon-skipping-programs-at-2026-muscular-dystrophy-association-clinical-and-scientific-congress</guid>
<pubDate>Thu, 26 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 26, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will present at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference, taking place March 8 - 11, 2026, in Orlando, Florida.</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-developments</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-developments</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Net product revenues for the full year 2025 totaled $1,864.3 million, consisting of $965.6 million of PMO net product revenue and $898.7 million of ELEVIDYS</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-commercial-launch-of-elevidys-in-japan</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-commercial-launch-of-elevidys-in-japan</guid>
<pubDate>Tue, 24 Feb 2026 14:07:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 24, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced the commercial launch of ELEVIDYS (delandistrogene moxeparvovec) in Japan by Chugai Pharmaceutical Co., Ltd., following its reimbursement listing on Japan’s National Health Insurance (NHI) price list.</description>
</item>
<item>
<title>Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-to-present-at-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 24, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference at the Boston Marriott Copley Place in Boston, Mass. on Tuesday, March 3 at 1:50 p.m. E.T.</description>
</item>
<item>
<title>Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announce-fourth-quarter-133000729</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announce-fourth-quarter-133000729</guid>
<pubDate>Wed, 11 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 11, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2025 financial results after the Nasdaq Global Market closes on Wednesday, Feb. 25, 2026. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full-year 2025 financial results.</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington’s Disease</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-approval-clinical-133000099</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-approval-clinical-133000099</guid>
<pubDate>Wed, 04 Feb 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., February 04, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that Medsafe, the New Zealand Medicines and Medical Devices Safety Authority, has granted approval for its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT. Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investigational s</description>
</item>
<item>
<title>Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-positive-topline-three-year-embark-results-showing-elevidys</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-positive-topline-three-year-embark-results-showing-elevidys</guid>
<pubDate>Mon, 26 Jan 2026 05:00:00 GMT</pubDate>
<description>At a mean age of 9 years old, ELEVIDYS-treated patients achieved mean North Star Ambulatory Assessment (NSAA) scores above baseline three years after</description>
</item>
<item>
<title>Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-report-3-topline-210500016</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-report-3-topline-210500016</guid>
<pubDate>Fri, 23 Jan 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 23, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that on Monday, Jan. 26, 2026, at 8:30 am Eastern Time, the Company will host a webcast and conference call to present 3-year topline functional results from patients treated in Part 1 of EMBARK (Study 9001-301), the global, randomized placebo-controlled Phase 3 study evaluating ELEVIDYS (delandistrogene moxeparvovec-rokl) in ambulatory individ</description>
</item>
<item>
<title>Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-reports-preliminary-fourth-quarter-165800625</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-reports-preliminary-fourth-quarter-165800625</guid>
<pubDate>Mon, 12 Jan 2026 16:58:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 12, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today reports preliminary* fourth quarter and full-year 2025 net product revenues and cash, cash equivalents, restricted cash and investments on hand as of December 31, 2025, as part of its presentation today at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California.</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington’s Disease</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-submission-clinical-133000248</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-submission-clinical-133000248</guid>
<pubDate>Wed, 07 Jan 2026 13:30:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., January 07, 2026--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the submission of its clinical trial application (CTA) for Study SRP-1005-101, also known as INSIGHTT, to Medsafe, the New Zealand Medicines and Medical Devices Safety Authority. Pending approval, Sarepta expects to initiate this first-in-human clinical trial of SRP-1005 (formerly ARO-HTT) in the second quarter of 2026. SRP-1005 is an investiga</description>
</item>
<item>
<title>Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-present-44th-annual-jp-morgan-healthcare-conference-2026-01-05</guid>
<pubDate>Mon, 05 Jan 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-inducement-grants-under-nasdaq-listing-rule-5635c4</guid>
<pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity</description>
</item>
<item>
<title>Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-refinancing-approximately-291-million-125-convertible</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-therapeutics-announces-refinancing-approximately-291-million-125-convertible</guid>
<pubDate>Thu, 11 Dec 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced</description>
</item>
<item>
<title>Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne</title>
<link>https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-approval-begin-endeavor-cohort-8-evaluate-enhanced</link>
<guid isPermaLink="true">https://6ix.com/company/sarepta-therapeutics-inc/news/sarepta-announces-approval-begin-endeavor-cohort-8-evaluate-enhanced</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>Approximately 25 non-ambulatory participants will receive sirolimus as part of the regimen in Cohort 8 of the ENDEAVOR study, which is expected to begin</description>
</item>
</channel>
</rss>